Epidiolex

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced its financial results late Wednesday for the third quarter of 2022 and raised the mid-point of 2022 total revenue guidance. "Our execution across our business continues to chart a clear path to delivering on Vision 2025. We have...

Jazz Pharmaceuticals plc (NASDAQ: JAZZ), a global biopharmaceutical company and manufacturer of Epidolex, announced its financial results late Tuesday for the full year and fourth quarter of 2021 and provided financial guidance for 2022. "2021 was a transformative year for Jazz,...

Benzinga's PreMarket Prep airs every morning from 8-9 a.m. ET. During that fast-paced, highly informative hour, traders and investors tune in to get the major news of the day, the catalysts behind those moves and the corresponding price action for the upcoming session. On any given...

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) shares are retreating following the release of fourth-quarter results. GW Pharmaceuticals reported quarterly losses of 7 cents per share, which beat the consensus estimate by 68 cents . This is a 65% increase over losses of 20 cents per share from the same...

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) reported better-than-expected third-quarter revenues, thanks to strong sales of its cannabinoid epilepsy drug Epidiolex. The Analyst Bank of America analyst Tazeen Ahmad reiterated a Buy rating and $218 price target. (See track record here) Cantor...

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) shares are down after the company released its third-quarter earnings report Tuesday afternoon. Third-quarter earnings came in at a loss of 4 cents per share, which may not compare to estimates that called for an 87-cent loss. Sales came in at $90.971...

Cannabinoid-based drug maker GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) CEO Justin Gover told CNBC's Jim Cramer the company's approval to market Epidiolex across Europe is a "historic milestone" for the field of cannabinoid science. European Approval Epidiolex is the only CBD-...

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH)'s CBD drug Epidiolex, which treats epilepsy, has been deemed too expensive by the U.K.’s National Health Service, according to an iNEWS report. Epidiolex has been shown to be effective in limiting seizures in children...

GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH) opened higher by 8 percent Tuesday after posting positive results from its Phase 3 Epidiolex trial and second-quarter earnings beats. Here’s what analysts are saying. Epidiolex Sales GW Pharma closed out its first full quarter of Epidiolex sales...

Zogenix, Inc. (NASDAQ: ZGNX), which develops therapies for rare diseases, said Monday afternoon the FDA issued a refusal to file letter regarding its NDA for Fintepla, chemically fenfluramine hydrochloride, which is being evaluated for the treatment of seizures associated with Dravet syndrome. The...

Following its results for the first quarter of fiscal 2019, analysts at Cantor Fitzgerald provided an update about GW Pharmaceuticals plc (NASDAQ: GWPH). The Analyst Cantor Fitzgerald analysts Elemer Piros and Kristen Kluska reiterated the Overweight rating and $193 price target on GW...

GW Pharmaceuticals plc (NASDAQ: GWPH) reported its financial results Tuesday for the first quarter of fiscal 2019. The company reported revenue growth of  67.5 percent. One highlight: the report includes sales of the company's Epidiolex drug, which last year became the first cannabis-based...

Investors in GW Pharmaceuticals PLC (NASDAQ: GWPH) may need to sit through some short-term volatility as sales of the company's newly approved drug ramp up slowly because of insurance coverage issues, says the author of The 420 Investor. Alan Brochstein, who is a founding partner of New...

Bank of America Merrill Lynch doubled down on its bullish thesis for GW Pharmaceuticals plc (NASDAQ: GWPH) and its flagship Epidiolex drug after attending the American Epilepsy Society's annual meeting. The Analyst Analysts Tazeen Ahmad maintained a Buy on GW Pharma with a $190 price...

GW Pharmaceuticals plc (NASDAQ: GWPH) Epidiolex drug and earlier-stage programs Sativex and CBDV will represent major catalysts for the stock in the near-term, in Cantor Fitzgerald's view.  The Analyst Analyst Elemer Piros reiterated an Overweight on GW Pharmaceuticals with a $211 price...